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Abstract
Objectives: To determine the extent of shortfall in syringes by measuring the need from nationally validated
sources and comparing it with position on the supply side. This was done in order to contribute to the ongoing
national discussions that have focused on increasing syringe supply to curtail syringe reuse.
Methods: Using 'Injections received' data from the Pakistan Demographic Health Survey 2006-7 (N: 5429) and
the National Hepatitis Survey (N: 47,043), the study estimated the number of injections received in Pakistan. We
matched these against the local syringe production figures from the syringe manufacturers' association and
import figures from the Federal Board of Revenue (FBR).
Results: Approximately 731±867 million injections (5.1±12 injections per head) are received annually in Pakistan
and around 861±961 million syringes are supplied to the open market. Overall, 52-77% Pakistanis receive at
least one injection in any given year. 
Conclusions: Injection need in Pakistan is among the highest worldwide but is completely matched by available
syringe supplies, suggesting lower reuse than previously considered. However, highly prevalent Hepatitis B and
C viruses suggest that even this reuse is a major public health concern and measures directed at both providers
and recipients of injections are needed to curtail high injection need and syringe reuse.
Keywords: Therapeutic Injections, HIV, Hepatitis, HCV, HBV, Syringe, Supply and need. (JPMA 62: 1149; 2012)
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Introduction
Unsafe injection practices, including excessive use
of therapeutic injections and reuse of syringes, are major
public health hazards and have likely contributed to the high
prevalence of Hepatitis B and C1-6 which now infect over 12
million people nationwide.1 A recent outbreak of HIV in
Gujrat (National AIDS Control Programme, 2009) has
further highlighted the concerns for iatrogenic transmission
of infections among the general public.
Therapeutic injections are commonly sought and
administered in Pakistan4,7 and are often unnecessary.8 The
majority are given in the private sector as most public-sector
facilities seldom provide injections. This overuse is driven
by a popular belief among healthcare providers and patients
that injections are more effective and provide quicker relief
than orally administered medicines.6,9,10 Some patients even
feel that a doctor's fee is unjustified unless an injection is
given.11 Some data suggest that syringe reuse is common
with no or minimal attempts at sterilisation such as soaking
in diluted alcohol or tepid water or simply wiping the needle
with alcohol swabs.7,11,12 These practices are further
perpetuated by limited awareness among patients (and
possibly some providers) about the hazards of using
unsterilised needles such as transmission of Hepatitis B or
C and HIV infections. Additionally, there is a strong belief
that the 'doctor knows best', hence, when injections are
prescribed or syringes are reused by doctors, patients
seldom object.10,11 For their part, some providers would
rather prescribe placebos or non-medicated injections such
as distilled water or saline rather than take the time to
explain the lack of need for an injection.11
There is an ongoing debate in Pakistan that limited
supply of syringes may be driving their reuse. Previous
estimates of the number of therapeutic injections received
have ranged from 4.37 to over 103 per person annually;
suggesting a national requirement for 0.7 to 2.5 billion
syringes annually. Meanwhile, presentations by trade
groups and some public health professionals have suggested
that the national supply may be around 300-330 million,
thus giving a shortfall of between 400 million and 2 billion
syringes a year. This has led to the argument that individuals
with limited resources are unable to purchase and use fresh
needles each time they require injections, resulting in
widespread reuse of syringes for therapeutic injections.
National groups have, therefore, argued for increasing the
national supply by as many as 1-2 additional billion
syringes annually. On the other hand, the static national
prevalence of Hepatitis B and C over the past decade13
suggest that syringe reuse may be less common than is
speculated. 
The study explored the need and supply of syringes
for therapeutic injections in Pakistan to understand the
dynamics of syringe reuse. Previous estimates of national
injection frequency had been based mainly on small studies
that were from limited locations and often done in response
to outbreaks of Hepatitis, thus likely to overestimate the
injections received. We calculated the total need for
syringes for therapeutic injections by analysing data of two
large national population level studies and compared this
with the current supply of syringes in Pakistan to estimate
the proportion of injections given with reused syringes. 
Material and Methods
The need for therapeutic injections in Pakistan was
calculated from a population level study conducted by Pakistan
Medical Research Council (PMRC) and the Pakistan
Demographic Health Survey (PDHS), both of which asked
subjects about therapeutic injections received during the
preceding year. The data for the domestic syringe production in
Pakistan was provided by the national syringe manufacturer's
association: Pakistan Disposable Medical Equipment
Manufacturers Association, a trade group. The Federal Board
of Revenue (FBR) informed about imports. Collectively they
accounted for the supply of injections in Pakistan.
In the PDHS 2006-7 a nationwide probability
sample of 5249 women aged 15-49 were surveyed about
their health and healthcare seeking including the number of
medical injections received in the preceding 12 months. We
proportioned these data to seven age groups and ascertained
the average for the number of injections received by each
age group. Since the survey excluded age groups below 15
years and above 49 years, we applied the assumption that
the average of 15-19 years applied to the <15 group and the
45-49 group applied to the >49 group. Total number of
injections received by women nationwide were then
calculated by multiplying the mean injections received by
each age group with the total population of women in
Pakistan in that group as described by the Federal Bureau of
Statistics (FBS). Since the PDHS interviewed only women,
the number of injections for men was calculated by
multiplying the injections for women with the FBS's
national ratio of men to women i.e. 1.085: 1 (Table-1). The
total number of injections received in Pakistan were then
calculated by adding the totals of each age group.
In a study by the PMRC, a nationally representative
sample of 47,043 men, women and children were asked about
risk factors for Hepatitis B and C, including the number of
injections received in the previous year. These injections were
recorded in ranges of 2-4, 5-10 etc. These ranges were collapsed
to a mean: a range of 2-4, for instance, meant an average of 3
injections with the lower limit of 2 and upper limit of 4. We
divided the study subjects into the same age groups as was done
with the PDHS and then multiplied the mean number of
injections by each of the age group with the total population of
Pakistan in that group; the national total of injections received
were calculated by adding the totals of each age group. Neither
study asked about vaccines received and, therefore, the
estimates of injections represented only therapeutic injections.
Syringes are both imported and manufactured in
Pakistan. We obtained the estimates of the total number of
syringes imported into Pakistan from the Federal Board of
Revenue (FBR) that levies taxes on all imports, and
accounted for all imports. Estimates of the syringes
manufactured locally were obtained from the Pakistan
Disposable Medical Equipment Manufacturers Association,
which is a trade group with membership from over 20 of the
largest syringe manufacturers in Pakistan. They also
provided estimates of syringes manufactured by one large
company that is outside the Association. The Association
data likely includes over 95% of all syringes manufactured.
Thus putting the 2 sources together, we likely accounted for
around 90-95% of all syringes available in Pakistan.
Since this is an analysis of publicly available
secondary data that did not involve human subjects directly
(both constituent studies had appropriate ethical oversight),
no additional ethical approval was sought for the study.
Results
The PDHS data suggests that 731±867 million
injections were received in Pakistan, or approximately 5.1±12
injections received per head per year (9.6 per head if one
excludes the 48% subjects that never received any injections).
Estimates from the PMRC study suggested that a
total of 709±604 million injections were received
nationwide. Thus, the total number of injections received
was 4.3±3.8 per person per year (5.3 if one excludes the
23% who never received injections) (Table-1). 
Supply data estimated that about 450 million
syringes were imported per year of which around 30 million
annually were for vaccines and 10 million were insulin
injections. Local manufacturers produced between 744-804
million regular single-use and approximately 10 million
auto-disable syringes annually and estimated that around
25% of all syringes were sold to laboratories for diagnostic
blood draws. No appreciable quantities of syringes were
exported. Thus, the market supply of syringes for
therapeutic injections was 861 to 961 million per year in
Pakistan or an excess of 152-175 million syringes compared
to the numberof injections being received (Table-2).
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Discussion
This was the first study to compare the overall
national need for syringes for therapeutic injections against
the supply of syringes. Using 2 large studies that recruited
subjects from nationwide probability samples, we estimated
that around 709-731 (4.3-51) million therapeutic injections
are received in Pakistan, excluding injections for insulin,
vaccines and syringes supplied to injection drug users via
government programmes. This figure is lower than what has
been previously cited and is at least matched by the supply of
syringes. Thus syringe shortage is unlikely to explain syringe
reuse as has been previously claimed.
At 4.3-4.6 injections per head annually, the overall
injection frequency in Pakistan is among the highest
worldwide.14,15 International data suggest that in countries
with comparable health systems and quality standards,
around 2 therapeutic injections per person are received
annually (sub-Saharan Africa: 0.9-3,15 parts of Asia: 1.2 to
2.115 and Latin America: 1.2 - 2.77) and is consistent with
data from Pakistan where prescriptions by formal providers
include an average of 1.5 injections9 and up to 94% of all
injections considered unnecessary.8 However, injection
overuse without syringe reuse will not increase transmission
of blood-borne infections. Literature suggests that syringes
are reused in 17% to 50%1,3,10,16 of all injections in Pakistan
and up to 94% in some other countries.17
We found that the national availability of syringes
slightly exceeds the need. Syringe reuse of 17-50% would
mean that about 120-400 million syringes would be surplus in
the market during any given year. Such an over-supply would
have lowered the price of syringes and/or caused local or
generalised gluts of syringes across the country. Prices of
syringes have not fallen and the syringe manufacturers'
association reports no gluts or supply inconsistencies. Thus,
while higher reuse is reported from some localities,18 the
average reuse is much lower nationwide. This is consistent
with the observation that national prevalence of Hepatitis B
and C have remained stable for the past decade,13 suggesting
limited iatrogenic transmission of these infections. However,
even this limited transmission has been sufficient to yield an
overall national prevalence of 2.5% for Hepatitis B and 5% for
Hepatitis C, which for Pakistan means that over 12 million
individuals are infected with either Hepatitis B or C virus.1
The matched supply and need for syringes suggest
that supply shortages are unlikely to explain reuse. This is
further supported by the fact that average injections in
Pakistan costs around Rs. 40 (USD 0.5)19 or more, and the
cost of an ordinary single-use syringe (Rs. 2-7 or USD 0.03-
0.09) is a small fraction of this cost. Since patients are
seldom aware of this breakdown, it is highly unlikely they
determine reuse. It is likely that majority of reuse is by a few
providers only.
Efforts to reduce injections or syringe reuse in the
medical sector must involve both providers and their patients.
Provider interventions would include re-training providers in
the correct indications for injections and re-emphasising the
risks of injections such as infections and injection injury,20
establishing quality standards for medical care that promote
these principles and ensuring that these standards are
followed. This will require addressing medical or other pre-
service training of medical care providers and be reinforced
periodically with in-service refreshers. Enforcing any of this
will be difficult as most of the healthcare in Pakistan21 and
nearly all injections (including most that are prescribed in the
public sector) are given in the private sector, many in
conditions of uncertain sterility and with reused equipment.22
Given this scenario, the most efficient approaches
would likely be those that target patients and may include
mass media campaigns and community/interpersonal
outreach such as the Health Ministry's large-scale Lady
Health Workers Programme. These efforts would inform the
public about the lack of necessity of therapeutic injections in
most clinical scenarios, emphasise the risks involved with
such injections and encourage patients to insist on new
syringes for the injections they receive, hence making them
better consumers of healthcare.
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Table-2: Annual Supply and Availability of Syringes (in Millions).
Total Availability 1194 - 1254
Local production/ year 744-804* + 10 auto-disable
Imports (CBR Data)/ year 450
Total Usage Other Than For Therapeutic Injections 333 - 348
Estimated Vaccine and Insulin syringes (From imports) 40
Injections used in Laboratories (25%) 291 - 306
Injections supplied to Injection Drug Users by HIV prevention programs 2
Syringe Supply To Market For Therapeutic Injections 861 - 961
Syringe Need 709-731
Pakistan Medical Research Council Survey (N ± SD) 709 ± 604 
Pakistan Demographic Health Survey (N ± SD) 731 ± 867 
Excess Availability of Syringes for Therapeutic injections 152 - 175
* Syringe Manufacturers' data.
The use of single-use equipment, such as auto-
disable syringes, has been discussed nationally. These
constitute roughly 1-2% of the current syringe supply and
are slightly more expensive (Rs. 7-9 or USD 0.09-0.11) than
regular syringes. However, since reuse seems driven largely
by a few providers who may be financially motivated to
reuse single-use equipment, the role of auto-disable
syringes is uncertain unless they are either the only kind of
syringes available or have their use enforced by law; both
seem distant possibilities at present.
The study had several limitations. We used third
party data which were not primarily intended for a syringe
need analysis. Besides, we made a number of assumptions
that may have introduced errors in either direction. For
example, in the PDHS data, we assumed that men received
the same number of injections as age-matched women. This
could be higher for men due to higher access to healthcare.
In fact, the PMRC data suggests that men receive about 5-
10% more injections, which, while significant, represents a
small difference in the total number of syringes. Similarly,
in the PDHS we extrapolated data for <15 and >49 age
groups. It is likely that the younger group actually receives
fewer and the older group receives more injections.
However, since proportion of population <15 years is huge
and those >49 are few, our estimates may have exaggerated
the actual number of injections nationwide. Finally the data
provided by the syringe manufacturers, is an estimate.
Actual production and supply to laboratories varies on a
monthly and yearly basis, although within a ±10% range.
Conclusion
The study demonstrated that the huge need for
therapeutic injections in Pakistan is completely met by the
supply of fresh syringes, suggesting that syringe reuse is
likely lower than previously considered and may be driven by
provider factors. A number of measures aimed at providers
and patients are needed to curtail injection overuse and
syringe reuse. These measures must be informed by better
understanding of patients' desire for injections, trials of
interventions that reduce injection demand and enhance new
syringe use and modalities to effectively train medical care
providers (including non-doctors) to use injections
judiciously. These efforts will require a combination of
research and effective government programmes to train
providers and enforce regulations.
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